Celcuity Inc. surges to a $2B valuation on strong phase 3 data for gedatolisib in hormone-positive breast cancer. Read why ...

Low-dose aspirin reduced colorectal cancer (CRC) recurrence rates by more than half in patients with tumors harboring mutations in the PI3K signaling pathway, according to findings from the phase 3 ...

PI3K Pathway Aberrations May Reveal Targeted Therapy Opportunities Combination therapies targeting both mutations in the PI3K pathway and HER2 or hormone receptor overexpression should be evaluated, ...

Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS and a key ...

Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS, and a key ...

Researchers found that 160 milligrams of daily aspirin significantly lowered cancer recurrence risk for colorectal patients ...

The emergence of drug resistance remains one of the greatest challenges in effective cancer therapy. Despite advances in ...

Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue [NRAS], ...

An international research team has identified a previously unknown mechanism by which the breast cancer drug tamoxifen can increase the risk of secondary tumors in the uterus. Subscribe to our ...